Treatment Outcomes of Newly Diagnosed Epilepsy
The Worldwide estimation states that epilepsy is one of the most common yet serious chronic neurological disorders with an incidence of 68 per 100000 persons per year. Understanding the multi-faceted treatment outcomes of newly diagnosed epilepsy is critical for developing rational therapeutic strategies. The aim is to understand seizure outcomes in children and adults with newly diagnosed epilepsy through method especially designed to give systemic review and meta-analysis of longitudinal observational studies. The study shows two outcomes namely primary and secondary and both the outcomes are graphically explained in detail. We can conclude that one can achieve seizure freedom with currently available ASMs in most patients. Future research suggest that one should aim to increase the proportion of patients with early and sustained seizure freedom by choosing the ‘right drug’ at the first trial, develop novel therapies to overcome pharmacoresistance, and design disease-modifying treatments targeting specific disease mechanisms.
ASM- Antiseizure medications, C1YSF- cumulative 1-year seizure freedom
- Janmohamed M, Hakeem H, Ooi S, Hakami S, Vu L, Perucca P, O’Brien TJ, Antonic-Baker A, Chen Z, Kwan P. Treatment Outcomes of Newly Diagnosed Epilepsy: A Systematic Review and Meta-analysis. CNS drugs. 2022 Dec 21:1-8.